Skip to content

R&D at other companies

The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$42.5M-6.6%
Glaukos logo
GlaukosGKOS
$44.15M+36.4%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$22.35M+55.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.54B+16.3%
Organon logo
OrganonOGN
$93M-3.1%
Solventum logo
SolventumSOLV
$189M-2.1%

Segments

By segment

See full
Pharmaceuticals$22M+144%
Surgical$13M+18.2%
Vision Care$10M+25.0%

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's R&D?
Bausch + Lomb (BLCO) reported R&D of $101M in Q1 2026.
How has Bausch + Lomb's R&D changed year-over-year?
Bausch + Lomb's R&D increased by 17.4% year-over-year, from $86M to $101M.
What is the long-term trend for Bausch + Lomb's R&D?
Over 4 years (2021 to 2025), Bausch + Lomb's R&D has grown at a 8.2% compound annual growth rate (CAGR), from $271M to $371M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.